EUVIMEDEUVIMED entdecken
Crossref

The opening gambit: CheckMate 159 and the immunotherapy neoadjuvant era in non-small cell lung cancer

Igor Gómez-Randulfe, Raffaele Califano

AME Clinical Trials Review · 2023

DOI: 10.21037/actr-23-37 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AME Clinical Trials Review, 2023. Verfasst von Igor Gómez-Randulfe und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Gómez-Randulfe, I., & Califano, R. (2023). The opening gambit: CheckMate 159 and the immunotherapy neoadjuvant era in non-small cell lung cancer. AME Clinical Trials Review. https://doi.org/10.21037/actr-23-37

Vancouver

Gómez-Randulfe I, Califano R. The opening gambit: CheckMate 159 and the immunotherapy neoadjuvant era in non-small cell lung cancer. AME Clinical Trials Review. 2023. doi:10.21037/actr-23-37

BibTeX
@article{GmezRandulfe2023,
  author = {Gómez-Randulfe, Igor and Califano, Raffaele},
  title = {The opening gambit: CheckMate 159 and the immunotherapy neoadjuvant era in non-small cell lung cancer},
  journal = {AME Clinical Trials Review},
  year = {2023},
  doi = {10.21037/actr-23-37}
}
Kostenlos starten →